Lundbeck presents updated Phase II data on asedebart in Cushing’s disease at ENDO 2026. Asedebart is an investigational monoclonal antibody intended to neutralize excess adrenocorticotropic hormone (ACTH). By targeting ACTH, the therapy aims to reduce downstream cortisol production, addressing the underlying hormonal imbalance in Cushing’s disease.
The company highlights urinary free cortisol (UFC) normalization as an important clinical measure in Cushing’s disease. UFC reflects levels of cortisol circulating over a collection period and is commonly used to assess whether cortisol production has returned toward normal ranges. Lundbeck’s presentation focuses on the reported outcomes of the Phase II study, including how patients’ UFC levels respond to treatment.
Across the information provided, the key focus is the mechanism of action of asedebart—ACTH neutralization leading to lower cortisol—and the use of UFC normalization as a clinically meaningful endpoint. No additional details on comparator arms, study size, statistical significance, or safety findings are included in the provided excerpt.
